Download Image
    
Share
  
Post
AZD5156 for COVID-19
1 study with 57 patients
Hospital Icon Control
Hospital Icon AZD5156 Serious Outcome Risk
No significant improvements are seen in meta-analysis to date.
COVID-19 AZD5156 studies. Jul 2026. c19early.org
0 0.5 1 1.5+ All studies -139% Mortality -139% RCTs -139% Prophylaxis -139% FavorsAZD5156 Favorscontrol
Recent:
Haidar.
Jun 18
 Haidar et al., NCT05648110 Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)
139% higher mortality (p=1). RCT 57 patients showing no significant differences with AZD5156 (sipavibart + cilgavimab).